These risk factors may be used in this way to identify people at high risk so that intervention may be directed towards them. In population terms this may be a profitable approach as the top 15% of the risk distribution may provide 32% of the cases of myocardial infarction over the subsequent five years. For individual people, however, the accuracy of the prediction is low: among those without initial evidence of coronary heart disease only 7% characterised as being at high risk will actually develop a myocardial infarction in the subsequent five years. Prevention has been suggested to be more effective in those with initial ischaemia.12 13 Even in this group, however, only one fifth of those characterised as being at high risk will develop a myocardial infarction in the subsequent five years. This discrepancy between the importance to the population as a whole and that to a single patient may explain some of the difficulties of persuading people of the potential benefits of reducing risks.8 Introduction Several reports have emphasised the poor clinical outlook for patients with myelomatosis who develop renal failure.'-8 It is not clear, however, that this is due entirely to death from renal failure itself. The incidence of renal failure is considerably higher than the death rate attributable to this cause. 7 The single factor most commonly implicated in the induction of renal lesions in myelomatosis is free light chain. 9 10 Nevertheless, only a proportion of patients with light chain proteinuria develop renal failure. This has led to the widely held concept of the existence of nephrotoxic and non-nephrotoxic light chains. 9 Although the nephrotoxic potential of different light chains may vary,11 12 this may not be the major reason why many patients with light chain proteinuria escape renal failure. An alternative hypothesis is that most if not all light chains cause tubular dysfunction but that this does not by itself reduce the glomerular filtration rate. Rather, it facilitates the precipitation of renal failure by other factors. If correct, this implies that measures apart from those to reduce the amount of light chain reaching the kidney may be of therapeutic value.
In planning the fourth MRC myelomatosis trial two measures were assessed for treating patients presenting in renal failure-(a) the maintenance of a high fluid intake, and (b) the administration of bicarbonate in sufficient quantity to render the urine neutral. This report analyses the clinical course of 80 patients who presented in the trial with renal failure and who were managed by these two methods. It also examines factors that may be associated with the response of renal failure to treatment and gives a detailed study of the causes of death in patients presenting with myelomatosis in renal failure.
Patients and methods
Between 1 March 1980 and 28 February 1982, 522 patients with myelomatosis were admitted to the fourth MRC myelomatosis trial. All patients were followed up till death or to 1 April 1983. Criteria for entry were as for the previous MRC trial.5 Only patients aged under 75 were included.
ENTRY TO RENAL STUDY
All patients entering the main trial whose blood urea concentration exceeded the normal range received an initial 48 hours of hydration. Serum creatinine and blood urea concentrations were then reassessed, and patients whose blood urea concentration was still > 15 mmol/l (>90 mg/ 100 ml)-that is, those whose raised blood urea value was not attributable to haemoconcentration alone were admitted to the renal study. After 1 June 1981 patients whose serum creatinine concentration was >200 ,umol/l (>2-3 mg/100 ml) but whose blood urea value was <15 mmol/l were also included, as in the first part of the trial there had been a high early mortality in this group.
RENAL STUDY MANAGEMENT
The 80 patients entered into the study were, with seven exceptions, treated with a continued oral fluid intake of at least 3 1/24 h. The exceptions were three patients with oliguric renal failure not reversed by dialysis and four patients with poorly controlled congestive cardiac failure. A further four patients presented in oliguric renal failure but managed to tolerate a high fluid intake after an initial period of rehydration and dialysis. In addition to a high fluid intake, patients were randomised to receive either sufficient oral sodium bicarbonate to render the urine neutral or no supplement. Irrespective of randomisation, any patient whose plasma bicarbonate concentration was below 20 mmol (mEq)/l was encouraged to take alkali until the concentration had returned to this value or above.
CHEMOTHERAPY
Patients in the renal study were randomised to one of the two chemotherapy arms being tested in the main trial.
Arm (a) comprised courses of melphalan 10 mg daily by mouth for seven days with prednisone 40 mg daily by mouth for seven days. If the blood urea concentration exceeded 10 mmol/l (60 mg/100 ml) melphalan was given as four day courses. Patients with oliguria received melphalan in a dose of 5 mg daily for four days. Courses were repeated at intervals of four weeks between the first day of one course and the first day of the next. In the event of myelotoxicity reduction of courses by one or more days was permitted. If intervals between courses had to extend to six weeks or more for three successive courses because of myelotoxocity the treatment was changed to cyclophosphamide 600 mg/M2 intravenously every three weeks.
BRITISH MEDICAL JOURNAL VOLUME 288 12 MAY 1984 Arm (b) comprised the same regimen as (a) but with the addition of vincristine 1 mg intravenously on the first day of each course. at two years 28%. The survival prospects for all 522 patients entered into the trial were 76% at one year and 52% at two years. Figure 1 also shows the survival rates among the 54 patients entered into the third myelomatosis trial whose blood urea concentration was 15> mmol/l (> 90 mg/100 ml) before chemotherapy but after the initial 48 hours of hydration. Both groups had a high early death rate. The chemotherapy and management policy in the third trial differed from that in the fourth trial. Details of this have been published.5 In the third trial 37 (69,') of the 54 uraemic patients had died within 100 days of entry; in the fourth trial 31 (39' ) of the renal study patients had died by that time. After 100 days the death rate in both trials slowed appreciably. The effect of presentation blood urea values on survival in all 522 patients in the fourth trial was dramatic-2 for trend 42 6; p<0 0001. When presentation blood urea concentration was assessed for survival prospects among the 422 patients surviving 100 days from entry its prognostic significance was considerably less (fig 2; x2 for trend 6 6; p=0 01). Days from entry Ismol/l (< 1 5 mg/100 ml); the group with partial resolution comprised 21 patients with a sustained reduction in serum creatinine concentration, though at a value above 130 ,umol/l (range 845-148 (median 241)
,mol/l; 9-6-1 7 (median 2 7) mg/100 ml)); and the no resolution group comprised eight patients, two of whom were in oliguric renal failure and were maintained by dialysis. Figure 4 shows the relevance of these three categories to survival. Factors that might affect renal state in these groups and the 31 patients who died within 100 days of entry to the study are analysed below. Serum calcium concentration was raised (>2 6 mmol/l (> 10-6 mg/ 100 ml) after correction for serum albumin value by adding 01 mmol/l (0-4 mg/100 ml) to calcium for every 6 g/l by which serum 16 (52%) had raised serum calcium concentrations. In the groups showing complete, partial, and no resolution of renal failure raised serum calcium concentrations were seen in 9 (500O), 11 (52o/o), and 3 (38 X) respectively. The prevalence of hypercalcaemia at presentation in the 442 non-renal study patients (2300) was lower than that in any of the renal study groups.
Serum creatinine concentrations- Figure 5 shows the serum creatinine concentrations at presentation in the four groups defined above. More patients achieving complete resolution of renal failure had serum creatinine concentrations of 200-300 yimol/l (2-3-3-4 mg/ 100 ml) than in any other group. Three patients with concentrations 1600- had a pyogenic infection requiring medical attention in the year up to diagnosis of myelomatosis. The same proportion of renal study patients had pyogenic infection in this period.
CAUSES OF DEATH IN RENAL STUDY
Careful analysis of cause of death was made in all patients dying in the renal study. It was difficult to assign a single cause of death in some cases. The principle followed was to identify the main factor precipitating the final episode-for example, someone with-uncontrolled growth of tumour who died with terminal bronchopneumonia was recorded as dying from tumour growth. Someone whose tumour seemed to be in control, who was not immobilised by bone pain, and who died from lobar pneumonia, however, was recorded as dying from pyogenic infection. Table II summarises above 1000 ,umol/l (11-3 mg/100 ml) at presentation, however, achieved normal values subsequently. Two of these presented in oliguric renal failure and underwent a short period of dialysis before achieving a good diuresis. They were then maintained with a high fluid intake.
Non-selective glomerular proteinuria (defined as more than 1 g trichloroacetic acid precipitable protein per litre of urine, of which a substantial proportion was of higher molecular weight than albumin and not simply paraprotein as shown by sodium dodecyl sulphate polyacrylamide gel electrophoresis) was present in 54 (10 30o) of the 522 patients entered into the trial, including 10 of the 80 patients in the renal study. Four patients had selective albuminuria. In the renal study group non-selective glomerular proteinuria was found in 10 of the 80 patients-in six of the 31 patients dying before 100 days, in two of the complete resolution group, and in two of the partial resolution group; it was not found in any patient of the no resolution group. Tubular function will be reported in detail elsewhere. Analysis showed that around two thirds of patients entered into the fourth myelomatosis trial had selective tubular proteinuria which correlated strongly with urinary light chain output. This correlation was seen both in patients with normal and in those with raised serum creatinine concentrations. Selective in this context means failure to reabsorb al microglobulin and a, acid glycoprotein but with retained capacity to reabsorb retinol binding protein, P2 microglobulin, and glucose. This is illustrated in figure 6 , which correlates oa, microglobulin concentrations in the urine in relation to urinary light chain output and renal failure. oc, Microglobulin is a 27 kilodalton protein which is normally reabsorbed in the proximal renal tubules. All patients in each of the renal study groups had tubular proteinuria.
Pyogenic infection at presentation-Pyogenic infection was a common feature in the trial patients as a whole. Of all 522 entrants, 100 (19-2°' ) EIFECT OF ALKALI ADMINISTRATION Treatment with alkali was randomly allocated to 40 patients. The remaining 40 were randomised to receive high fluid intake alone. The group allocated alkali administration fared slightly better in terms of survival than the control group (fig 7) . This difference, however, was not significant (log rank test; p 0-26). Discussion Analysis of renal failure in myelomatosis is complicated by the number of pathological processes that may affect the kidney in this disease.'0 15 It is also difficult to relate particular dysfunctions to the onset of renal failure-for example, both tubular and glomerular proteinuria may be present without raised concentrations of serum creatinine. In a second report on all 522 patients in the fourth MRC myelomatosis trial it will be shown that impaired tubular function is associated with light chain proteinuria even in patients not in renal failure. The present study, from a different set of observations, supports the conclusion that light chain alone is not sufficient to precipitate or sustain renal failure. Four patients already in renal failure reverted to normal glomerular filtration rates despite continued light chain production.
There may be several factors in the onset of renal failure in patients with light chain associated tubular dysfunction. Difficulty in conserving water and salt is likely to be of central importance. Dehydration will also aggravate and be aggravated by hypercalcaemia, proximal tubular acidosis, and cast formation. Casts are amply documented as a special feature of myelomatosis, but renal biopsy studies suggest that they are not invariably associated with renal failure. '6 -18 Shutdown in glomerular filtration is not always associated with cast formation in other conditions.'9 Additional factors must therefore be considered. Cast formation is likely to be enhanced during phases of dehydration and reduced when a high fluid intake is maintained. Pyogenic infection may also help to precipitate renal failure. The similar incidence of pyogenic infection before treatment in the renal study patients and other patients in the trial implies that pyogenic infection in the former was not secondary to renal failure.
Giving supplements of bicarbonate was clearly not harmful. Continued high fluid intake itself, however, was associated with reversal of renal failure in many patients. In single case studies while the relatively basic protein myoglobin will not." In our patientS24 25 correlation between renal failure and the dominant isoelectric point of urinary light chain has not been apparent. Hill et al, however, reported an association between acidic electrophoretic mobility of light chains and the induction of renal lesions.26 At low pH light chain may be precipitated in the lumen of the tubules. In addition, the reabsorption of light chain by proximal tubules has been shown to be reduced. 24 In vitro studies show that light chain reabsorption is not affected by a number of agents affecting renal tubular transport mechanisms.27
In setting up this study the evaluation of fluid intake as a randomised variable in the management of renal failure could not be justified ethically, and therefore we do not know why patients presenting in renal failure survived longer than in other trials in which chemotherapy as well as the fluid intake policy was different. These may, however, have been less important than the physicians' belief in the poor prognosis associated with renal failure in myelomatosis. A figure) . A coaxial catheter (French 3) was inserted through the larger catheter, manipulated into the tumour vein ( figure) , and a mixture of 0-5 ml absolute alcohol and 0 5 ml contrast medium (iohexol) injected into the tumour. The sclerosant mixture filled the venous network of the tumour and rapidly abolished flow in the opacified vessels.
After the procedure the patient experienced a little discomfort in her left loin, which was controlled with mild analgesics, and a fever of 38'C subsided after three days without antibiotics. Labetalol and hydralazine were withdrawn and her blood pressure remained well controlled. She was discharged home taking spironolactone (200 mg daily) only, which was stopped six weeks later. Computed tomography six weeks after the procedure showed a reduction in tumour size, and a 75Se cholesterol scintiscan showed normal uptake on the right but no uptake in the left adrenal gland. Blood pressure and plasma aldosterone and plasma and urine electrolyte concentrations remained normal when she had stopped all drugs. Twelve months after tumour ablation the patient remained normokalaemic without spironolactone and had needed only a small dose of a 3 adrenoceptor antagonist (oxprenolol 40 mg twice daily) to control her blood pressure.
Comment
Conn's tumours are usually hypovascular4; this and the fact that the adrenal gland receives its arterial supply from at least three different sources mean that it is not feasible to embolise these tumours by the arterial route, the approach normally employed for tumour embolisa- 
